From Yahoo Finance: 2025-06-20 16:07:00

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is undergoing a leadership transition as Richard Geary, Ph.D., prepares to retire in January 2026. Holly Kordasiewicz, Ph.D., will take over as the new executive vice president and chief development officer. Dr. Kordasiewicz brings over 20 years of R&D experience, particularly in neurology, and has led key programs with Biogen. Geary will remain a strategic consultant until 2026. Ionis focuses on RNA-targeted therapies and has a robust pipeline of treatments for various conditions. The company collaborates with leading pharma firms to develop transformative RNA therapies.

As Geary transitions out of his role, Kordasiewicz will take over as the new executive vice president and chief development officer. Ionis Pharmaceuticals, Inc. specializes in RNA-targeted therapies and has several approved products for different conditions. Geary will continue as a strategic consultant to ensure continuity. Kordasiewicz brings extensive R&D experience, particularly in neurology, and has contributed to key partnered programs with Biogen. Ionis is committed to developing transformational therapies for patients with serious diseases.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is making leadership changes as Richard Geary, Ph.D., prepares to retire in January 2026. Holly Kordasiewicz, Ph.D., will take over as the new executive vice president and chief development officer. Geary has been instrumental in bringing several medicines to regulatory approval. Kordasiewicz brings over 20 years of R&D experience, particularly in neurology, and has led key programs with Biogen. Ionis focuses on developing RNA-targeted therapies for various conditions and collaborates with leading pharma firms to expand its reach in transformative RNA therapies.



Read more at Yahoo Finance: Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire